Sichuan Hebang Biotechnology Co Ltd (603077) - Net Assets
Based on the latest financial reports, Sichuan Hebang Biotechnology Co Ltd (603077) has net assets worth CN¥18.77 Billion CNY (≈ $2.75 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥29.29 Billion ≈ $4.29 Billion USD) and total liabilities (CN¥10.53 Billion ≈ $1.54 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Sichuan Hebang Biotechnology Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥18.77 Billion |
| % of Total Assets | 64.06% |
| Annual Growth Rate | 24.18% |
| 5-Year Change | 68.09% |
| 10-Year Change | 188.75% |
| Growth Volatility | 39.45 |
Sichuan Hebang Biotechnology Co Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Sichuan Hebang Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 603077 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Sichuan Hebang Biotechnology Co Ltd (2009–2024)
The table below shows the annual net assets of Sichuan Hebang Biotechnology Co Ltd from 2009 to 2024. For live valuation and market cap data, see Sichuan Hebang Biotechnology Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥19.01 Billion ≈ $2.78 Billion |
-5.99% |
| 2023-12-31 | CN¥20.22 Billion ≈ $2.96 Billion |
+2.30% |
| 2022-12-31 | CN¥19.76 Billion ≈ $2.89 Billion |
+35.02% |
| 2021-12-31 | CN¥14.64 Billion ≈ $2.14 Billion |
+29.45% |
| 2020-12-31 | CN¥11.31 Billion ≈ $1.65 Billion |
-1.27% |
| 2019-12-31 | CN¥11.45 Billion ≈ $1.68 Billion |
+2.27% |
| 2018-12-31 | CN¥11.20 Billion ≈ $1.64 Billion |
-0.68% |
| 2017-12-31 | CN¥11.27 Billion ≈ $1.65 Billion |
+4.63% |
| 2016-12-31 | CN¥10.78 Billion ≈ $1.58 Billion |
+63.71% |
| 2015-12-31 | CN¥6.58 Billion ≈ $963.21 Million |
+38.52% |
| 2014-12-31 | CN¥4.75 Billion ≈ $695.38 Million |
+44.43% |
| 2013-12-31 | CN¥3.29 Billion ≈ $481.46 Million |
-3.36% |
| 2012-12-31 | CN¥3.40 Billion ≈ $498.22 Million |
+153.91% |
| 2011-12-31 | CN¥1.34 Billion ≈ $196.21 Million |
+37.58% |
| 2010-12-31 | CN¥974.62 Million ≈ $142.62 Million |
+32.13% |
| 2009-12-31 | CN¥737.62 Million ≈ $107.94 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sichuan Hebang Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3126.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥9.48 Billion | 50.88% |
| Common Stock | CN¥8.83 Billion | 47.41% |
| Other Comprehensive Income | CN¥1.14 Billion | 6.11% |
| Total Equity | CN¥18.63 Billion | 100.00% |
Sichuan Hebang Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of Sichuan Hebang Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BancFirst Corporation
NASDAQ:BANF
|
$3.84 Billion |
|
Asbury Automotive Group Inc
NYSE:ABG
|
$3.84 Billion |
|
Seaboard Corporation
NYSE MKT:SEB
|
$3.85 Billion |
|
Ypsomed Holding AG
SW:YPSN
|
$3.85 Billion |
|
Jiangsu Aucksun Co Ltd
SHE:002245
|
$3.84 Billion |
|
Garrett Motion Inc
NASDAQ:GTX
|
$3.84 Billion |
|
KINGDEE INT. UNS.ADR/100
F:KDID
|
$3.84 Billion |
|
FIELMANN AG (ADR/1/5)O.N.
F:FIE1
|
$3.83 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sichuan Hebang Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,575,342,485 to 18,626,392,431, a change of -948,950,054 (-4.8%).
- Net income of 31,464,686 contributed positively to equity growth.
- Dividend payments of 246,664,095 reduced retained earnings.
- Share repurchases of 1,196,788,701 reduced equity.
- Other comprehensive income increased equity by 1,072,144,033.
- Other factors decreased equity by 609,105,977.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥31.46 Million | +0.17% |
| Dividends Paid | CN¥246.66 Million | -1.32% |
| Share Repurchases | CN¥1.20 Billion | -6.43% |
| Other Comprehensive Income | CN¥1.07 Billion | +5.76% |
| Other Changes | CN¥-609.11 Million | -3.27% |
| Total Change | CN¥- | -4.85% |
Book Value vs Market Value Analysis
This analysis compares Sichuan Hebang Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 17.81x to 1.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.17 | CN¥2.97 | x |
| 2010-12-31 | CN¥0.25 | CN¥2.97 | x |
| 2011-12-31 | CN¥0.29 | CN¥2.97 | x |
| 2012-12-31 | CN¥0.66 | CN¥2.97 | x |
| 2013-12-31 | CN¥0.54 | CN¥2.97 | x |
| 2014-12-31 | CN¥0.74 | CN¥2.97 | x |
| 2015-12-31 | CN¥0.83 | CN¥2.97 | x |
| 2016-12-31 | CN¥1.32 | CN¥2.97 | x |
| 2017-12-31 | CN¥1.27 | CN¥2.97 | x |
| 2018-12-31 | CN¥1.21 | CN¥2.97 | x |
| 2019-12-31 | CN¥1.30 | CN¥2.97 | x |
| 2020-12-31 | CN¥1.31 | CN¥2.97 | x |
| 2021-12-31 | CN¥1.69 | CN¥2.97 | x |
| 2022-12-31 | CN¥2.20 | CN¥2.97 | x |
| 2023-12-31 | CN¥2.25 | CN¥2.97 | x |
| 2024-12-31 | CN¥2.19 | CN¥2.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sichuan Hebang Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.37%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.59x
- Recent ROE (0.17%) is below the historical average (9.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 6.81% | 5.23% | 0.27x | 4.89x | CN¥-20.65 Million |
| 2010 | 17.73% | 12.06% | 0.46x | 3.20x | CN¥75.34 Million |
| 2011 | 27.32% | 19.58% | 0.51x | 2.75x | CN¥232.19 Million |
| 2012 | 9.84% | 19.27% | 0.34x | 1.48x | CN¥-5.58 Million |
| 2013 | 1.96% | 4.02% | 0.29x | 1.70x | CN¥-264.58 Million |
| 2014 | 14.14% | 30.73% | 0.24x | 1.92x | CN¥196.55 Million |
| 2015 | 3.81% | 8.38% | 0.26x | 1.78x | CN¥-388.92 Million |
| 2016 | 3.04% | 9.18% | 0.27x | 1.24x | CN¥-727.87 Million |
| 2017 | 4.71% | 10.92% | 0.36x | 1.19x | CN¥-581.22 Million |
| 2018 | 3.31% | 6.04% | 0.45x | 1.21x | CN¥-734.14 Million |
| 2019 | 4.60% | 8.66% | 0.41x | 1.29x | CN¥-606.49 Million |
| 2020 | 0.37% | 0.78% | 0.36x | 1.32x | CN¥-1.07 Billion |
| 2021 | 21.19% | 30.22% | 0.56x | 1.26x | CN¥1.59 Billion |
| 2022 | 19.91% | 29.20% | 0.54x | 1.26x | CN¥1.89 Billion |
| 2023 | 6.56% | 14.54% | 0.36x | 1.25x | CN¥-674.29 Million |
| 2024 | 0.17% | 0.37% | 0.29x | 1.59x | CN¥-1.83 Billion |
Industry Comparison
This section compares Sichuan Hebang Biotechnology Co Ltd's net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $2,769,045,563
- Average return on equity (ROE) among peers: 6.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sichuan Hebang Biotechnology Co Ltd (603077) | CN¥18.77 Billion | 6.81% | 0.56x | $3.84 Billion |
| North Huajin Chemical Industries Co Ltd (000059) | $1.37 Billion | 0.00% | 0.79x | $1.28 Billion |
| Sichuan Chemical Co Ltd (000155) | $1.46 Billion | 0.78% | 1.16x | $4.82 Billion |
| Jiangsu Wujiang China Eastern Silk Market Co Ltd (000301) | $506.50 Million | 16.41% | 1.45x | $12.92 Billion |
| Zangge Holding Co Ltd (000408) | $304.26 Million | 8.29% | 1.38x | $20.72 Billion |
| Sichuan Jinlu Group Co Ltd (000510) | $1.46 Billion | 0.89% | 0.57x | $1.47 Billion |
| Jilin Gpro Titanium Industry Co Ltd (000545) | $269.12 Million | 8.73% | 0.27x | $438.99 Million |
| Aoyuan Beauty Valley Technology Co Ltd (000615) | $728.86 Million | 0.46% | 0.67x | $855.32 Million |
| Ningxia Younglight Chemicals Co Ltd (000635) | $934.64 Million | 13.67% | 2.94x | $472.35 Million |
| Maoming Petro-Chemical Shihua Co Ltd (000637) | $1.03 Billion | 8.78% | 0.45x | $362.87 Million |
| Inner Mongolia Yuan Xing Energy Co Ltd (000683) | $19.62 Billion | 9.23% | 0.83x | $4.87 Billion |
About Sichuan Hebang Biotechnology Co Ltd
Sichuan Hebang Biotechnology Corporation Limited provides agricultural, chemical, and new material products. It offers biological pesticides, biological veterinary drugs, and methionine products; and sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine. The company provides original glass and smart glass, special glass, low-e coated glass, and photovoltaic packaging … Read more